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Abstract
The management of Venous Thromboembolism in terms of treatments and prevention has been well researched for patients 
who have been discovered as positive for Factor V Leiden genetic clotting disorder, in either the homozygous or the heterozy-
gous genotype. In fact, the research and development of new agents called Direct oral anticoagulants aim to treat and prevent 
clotting events while minimizing the risks of bleeding. Although several risk factors have been identified in relation to VTE, Factor 
V Leiden mutation presents a seemingly higher risk due to its unpredictable incidences of clotting events, even in patients with 
optimal health characteristics. Yet, we haven’t transitioned to routine testing of the common population for the Factor V Leiden 
as a preventative measure, rather the focus has been on those at risk due to family history of VTE or if clinical decisions might 
depend on it, such as the proper choice of contraception for female patients. Additionally, the increased risk of thrombophilia 
during pregnancy raises concern for proper medical management that would benefit the mother, without harming the baby, at 
any point of the pregnancy.
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Introduction 
For many people, the thought of having a blood clot is 
terrifying and rightfully so because it is potentially fatal 
and essentially invisible. A blood clot can appear in the leg, 
in the lungs or even in the brain. Also called a thrombus, a 
clot represents an accumulation of blood in a solid state, 
essentially caused by coagulation processes. Although 
coagulation is an important and vital function of homeo-
stasis, the resultant clot formation may obstruct blood 
vessels enough to limit perfusion of their field of supply. 
Medicine has shown that many risk factors for developing 
thrombi are acquired and depend on a patient’s physi-
cal or medical conditions such as obesity, hypertension, 
atherosclerosis, or even pregnancy. However, different 
genetic mutations appear to be linked to increased risk 
of thrombosis, such as Factor V Leiden, named after the 
city of Leiden in the Netherlands, where it was first iden-
tified while researching links between oral contraceptives 
and increased cases of thrombosis (Vandenbroucke et 
al., 1994). Factor V Leiden is the most common genetic 
mutation causing increased risk of  thrombophilia, or ab-
normal coagulation, therefore treatment options should 
be carefully considered for patients with clotting histo-
ry, as well as preventative measures for those who have 
not presented with thrombi. In view of the association of 
blood clots with family planning measures, this review will 
focus on women with Factor V Leiden, considering female 
individuals with or without a history of thrombophilia.
Background: 
Pathophysiology of Factor V Leiden
The factor V Leiden thrombophilia, also called Activated 
Protein C resistance, stems from a genetic mutation that 
affects parts of the clotting cascade, a physiological pro-
cess necessary for proper regulation of coagulation (Van 
Cott et. al, 2016). More specifically, Activated Protein C 
(APC), along with a cofactor Protein S, normally inacti-
vates some coagulation factors, hence acting as an an-
ticoagulant system. The mutation results in a decline in 
that inactivation, which has the potential to increase the 
coagulation activity. As for all genetic mutations, they can 
be present as heterozygous with one abnormal copy of 
the gene, or homozygous, for which both copies of the 
gene are mutated, the latter increasing the risk for throm-
bophilia by 80-fold. Regarding the population distribution 
of the Factor V Leiden mutation, it appears to be more 
prevalent in Europe, followed by Africa, and less prevalent 
in America (Rees, Cox, 1995). 
Methods
To complete this review, multiple scientific scholar da-
tabases and peer-reviewed articles mainly found on the 
Touro College online library were used. The Proquest, 
Browzine, Google scholar, and Dynamed databases were 
utilized with specific associations of key words in order 
to optimize the research and the results necessary to 
complete this study.
Discussion
When exploring the Factor V Leiden mutation and its 
relation to increased risk of venous thrombosis, it is first 
essential to make the distinction between individuals who 
have had a previous clotting event such as a deep vein 
thrombosis or a pulmonary embolism and those who 
have not. In fact, treatment options, preventative measures 
and family planning possibilities may be affected by a pos-
itive history of thrombophilia, regardless of the presence 
of any physiological risk factors, not to be dismissed, but 
to be utilized in conjunction with factor Factor V Leiden 
mutation at the time of medical management (Anderson, 
2003). Those risk factors should be touched upon for ref-
erence and comparison throughout this review.
Non-genetic Risk Factors of Venous Thrombosis
The risk factors for VTE (venous thromboembolism) 
mainly consist of obesity, long periods of immobility, 
surgery, smoking, age, pregnancy and use of oral contra-
ceptive pills, according to the NYU VTEC center and the 
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Cornell center for blood disorders, both specializing in 
venous thrombosis. Although common knowledge sup-
ports their statement, others might argue about the true 
character of “risk factor” for some of the elements above 
mentioned. For instance, obesity appears as a weak link 
to increased VTE, based on multiple studies, therefore it 
should be carefully analyzed when considering treatment 
or even prophylaxis (Anderson, 2003). Similarly, although 
age seems to count as a risk factor for many diseases or 
medical complications, its direct connection to increased 
VTE is questionable, especially due to the variety of eth-
nicities throughout the world and their life standards, as 
described by an epidemiology review with respect to 
China presenting an impressively low rate of DVT per 
year (Cushman, 2007). Therefore, we should denote the 
importance of evaluating an association of physiological 
and potentially genetic risk factors when treating or pre-
venting venous thrombosis.
Treatments and Preventions of Venous 
Thromboembolism
It is essential to distinguish between patients who have 
had a VTE event and those who haven’t, as it may affect 
their treatment approach, even if they are positive for fac-
tor V Leiden. Additionally, this section will analyze wheth-
er treatments and preventions will be influenced by the 
homozygous vs heterozygous factor V Leiden status. 
When discussing treatment options, we refer to pa-
tients who have actually had a DVT or a pulmonary embo-
lism and require treatment with anticoagulant. Although 
the review focuses on patients with Factor V Leiden, it is 
important to make the comparison with patients who do 
not have any genetic mutation that would favor VTE, in 
order to better understand the rationale for treatment 
and prophylaxis.
Duration of Treatment
A minimum of 3-6 months of anticoagulation therapy is 
recommended for all patients who suffered a VTE, regard-
less of physiological or genetic risk factors (Kearon, Akl, 
2014). However, if a VTE is unprovoked, meaning without 
obvious risk factor, it is highly recommended to pursue 
anticoagulation for at least 12 months, or perhaps in-
definitely to avoid recurrence, as highlighted by multiple 
studies compiled in one of the articles on UPTODATE, 
an online medical reference, that strongly emphasized the 
reduction in rates of VTE recurrences in patients who 
had been on anticoagulation long term (Lip, Russell, 2019). 
Moreover, it is debatable whether a genetic mutation 
causes unprovoked VTE or if it is provoked by the mu-
tation. Even if provoked, opinions about the duration of 
treatment vary widely, especially if the patient’s genotype 
is heterozygous for factor V Leiden; in fact, many provid-
ers will not treat indefinitely for a VTE provoked by a 
genetic factor, (Lip, Russell, 2019). More surprisingly, the 
actual difference in VTE incidence between both Factor 
V Leiden genotypes seems questionable. Indeed, when 
analyzing the number of actual cases and the percentage 
of recurrence after a first event, only a slim difference 
between homozygous and heterozygous percentages in 
VTE events (Perez Botero, Ormsby, 2016). Therefore, we 
can argue that the Factor V Leiden genotype shouldn’t be 
used alone to distinguish between lengths of treatment. 
On a separate note, it is essential to take into con-
sideration the bleeding risk associated with taking anti-
coagulant agents, commonly named “blood thinners”. As 
a matter of fact, all anticoagulants increase the bleeding 
risk to some extent and require vital risk versus benefit 
assessment when initiating treatment for VTE and deter-
mining duration of treatment. Bleeding associated with 
anticoagulation can range from a simple  hematoma or 
easy bruising, to life threatening gastrointestinal or intra-
cranial hemorrhage (Garcia, Crowther, 2019). Evidently, 
the longer a patient is on anticoagulation treatment, the 
higher chances he/she has of developing internal bleeding 
events, and those shouldn’t be taken lightly, therefore 
must be investigated even with minimal symptoms, such 
as coughing up a little blood. In fact, the Mayo clinic rec-
ommends precaution when prescribing blood thinners 
especially to older patients (>75 years old) who present 
higher chances of GI bleed (Harringa, 2019). On a similar 
note, when treating a patient with factor V Leiden with 
anticoagulation on a long-term basis, one ought to care-
fully monitor the bleeding effect of the prescribed agent. 
Indeed, we can also include female patients with factor V 
Leiden, for which continuous anticoagulation therapy will 
result in heavier menstruations. Although, we previously 
Figure 1: Most common risk factors of Venous Thromboembolism
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argued that the factor V Leiden genotype alone doesn’t 
determine the length of treatment, those patients will 
need long term treatment since the factor V Leiden is a 
genetic component, and by definition cannot just disap-
pear, as opposed to obesity. Therefore, if it is a constant 
risk factor, it will most likely represent a constant threat. 
The next section will present various anticoagulants that 
have been discovered and manufactured.
Different Anticoagulants on the Market
Based on the table above, multiple factors are to be con-
sidered when initiating a patient on oral therapy following 
an acute VTE event, especially when the patient is positive 
for factor V Leiden, and will most likely require long term 
anticoagulation therapy The drug class can be taken into 
account . In this case, both warfarin and the rest of the 
agents called Direct Oral anticoagulants (DOACs) are 
acceptable for treatment of VTE (Milling, Frontera, 2017). 
Furthermore, the daily dosage varies among all AC agents, 
from once a day with Warfarin or Xarelto, to twice a day 
with Eliquis or Pradaxa. Therefore, it raises an obvious 
question of medication compliance. Surely patients would 
be more likely to comply with their medications if only 
they needed to be taken once a day instead of twice a 
day. In that respect, Warfarin or Xarelto seem to be op-
timal options. However, as indicated on the table above, 
the daily dose of warfarin is dependent on a standardized 
international blood test called INR. In fact, patients on 
warfarin need to check their INR blood test quite often 
as their dose of warfarin will be adjusted based upon the 
results. Therefore, the frequent change of coumadin dos-
age undoubtedly will result in patients confused with dos-
age, that is without considering frequent venipunctures 
to test the INR. In addition, warfarin is a vitamin K antag-
onist, which means all foods high in vitamin K will coun-
teract the effect of coumadin; hence, those foods should 
be avoided or eaten in small portions all throughout the 
duration of the treatment with 
warfarin; a factor to consider 
greatly since a lot of greens or 
even garlic can interact with war-
farin (Mayo Clinic, 2018).  
The next component of the 
table includes the creatinine 
clearance, representing a poten-
tial risk of certain DOAC agents 
such as Xarelto, on the renal 
function. Although it doesn’t di-
rectly concern a DVT or a PE, 
certain patients who present 
with blood clots events, may also 
suffer from other medical condi-
tions such as renal disease, which 
in this case can render the choice 
of AC more challenging. 
The last component of the 
table indicates the possibility 
to reverse AC agents due to 
overuse or excess bleeding for 
example as a result of hypovo-
lemic shock or major trauma. 
Warfarin’s reversal agent is Vitamin K. Moreover, a rever-
sal agent became approved by the FDA for both Eliquis 
and Xarelto this year, by the name of Andexanet Alfa 
(Cuker et. al., 2019).
Besides for the factors indicated on the table above, it 
is essential to also mention the potential risks of bleeding 
and consequent serious medical conditions such as GI 
bleed and intracranial hemorrhage. According to mul-
tiple trials, it appears that DOACs have a lower risk of 
intracranial hemorrhage or even GI hemorrhage than 
warfarin and therefore should be used as a first choice, 
if all contraindications have been carefully considered 
(Garcia, Crowther 2019).
Additionally, considerations must be made for female 
patients who are pregnant, because all the above-men-
tioned agents, whether Warfarin or DOACs are not indi-
cated during any of the stages of pregnancy. Alternatives 
Table 1: Oral Anticoagulant comparative table
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will need to be used as needed for treatment of a VTE 
during pregnancy or even as a prophylactic agent; those 
will be contemplated in the family planning section. 
The duration of anticoagulation treatment varies with 
the unprovoked versus provoked status of a VTE, in pa-
tients with either Factor V Leiden genotype, heterozygous 
or homozygous. A blood thinner treatment is designed to 
treat the current thrombosis, and even more importantly 
to prevent recurrence. The nature of the AC agent will 
depend on the availability of a reversible agent, the pa-
tient’s current renal status and the level of compliance a 
provider attempts to achieve, apparently more in favor of 
DOACs due to decreased risk of internal bleeding, com-
pared to warfarin. Recent tendency has it to get tested 
for genetic conditions such as Factor V Leiden, generally 
due to family history of clotting. Therefore, if a patient has 
a Factor V Leiden mutation, there may be some preven-
tative measures to consider in certain cases, even if that 
individual has never experienced a VTE.
Prevention of Venous Thromboembolism for 
Patients with Factor V Leiden
There are several non-genetic risk factors to venous 
thromboembolism (VTE), such as obesity, age, recent sur-
gery or long immobilization states. If we also consider 
the positive Factor V Leiden mutation genotypes, we can 
understand that certain patients are at serious risk for 
developing thrombi, whether from a physiological or ge-
netic standpoint, or both. Moreover, patients who have 
had a VTE can certainly develop another one, hence the 
necessity for treatment, and preventative measures. Let’s 
explore some risk factors and analyze the preventative 
measures that would best benefit those at risk.
First of all, we can raise the question regarding testing 
for genetic mutations such a factor V Leiden for patients 
who have had a VTE or are family members of Factor V 
Leiden. As a matter of fact, knowing that condition exists 
can be part the prevention process. It seems that new-
born or infant screening for Factor V Leiden or testing 
of the population is not recommended, however the rec-
ommendations seem strong for female patients of child 
bearing age with personal or family history of VTE, as well 
as those under 50 years of age with a personal history 
of Thromboembolism (Grody, et. al, 2001). While testing 
family members of Factor V Leiden genotypes carriers is 
important in certain cases, it appears it doesn’t necessarily 
prevent the occurrence of VTE, unless those patients are 
being educated on the mutation. It is especially important 
to educate about VTE risks and implications in different 
aspects of healthcare such as after a surgery, while on oral 
contraceptive or even during pregnancy (Segal et. al, 2009). 
Regarding the prophylactic interventions using med-
ications, patients undergoing surgery or long-term im-
mobilization following a surgery such as a knee or hip 
replacement, will be offered anticoagulation prevention 
via a low molecular weight heparin (LMWH). The most 
common of those agents is called enoxaparin, with brand 
name “Lovenox”, available as an injectable product, that 
can be self-administered by the patient, but requires sev-
eral calculations to determine proper dosage based on 
weight and monitoring with a blood test called the “Anti 
Xa activity” that calculates its efficacy (Busti, 2015). More 
precisely, the LMWH acts as an inhibitor of a factor Xa, 
one of several proteins involved in the coagulation cas-
cade, which results in clotting formation, either in a nor-
mal ratio or abnormal, with consequences such as VTE. .
Another commonly used agent for prophylaxis, es-
pecially following a surgery, is warfarin, previously men-
tioned. In fact, it may seem undesirable for a lot of pa-
tients to go through daily injections. Although the use of 
prophylaxis Warfarin has been associated with more than 
50 % reduction of VTE post orthopedic surgery, LMWH 
was concluded as a superior alternative for protection 
against thromboembolism post-surgery (Paj, Douketis, 
2019). Moreover, the use of low dose Aspirin has been 
contemplated as well for prevention of VTE but is most 
commonly used for cardiovascular prevention such as 
protection from strokes or myocardial infarctions. 
Although the goal of anticoagulant agents is for pre-
venting VTE, the bleeding consequences are not to be 
ignored. Therefore, hospital settings also offer non-phar-
macological options such as an IPC device, intermittent 
pneumatic compression device, that improves venous 
circulations in upper and lower extremities to prevent 
edema, as well as venous thromboembolism. However, 
since data hasn’t shown the IPC device as a complete 
alternative to medicated options, according to “uptodate” 
latest research(Paj, Douketis, 2019), it is becoming com-
mon practice to start off with IPC devices for patients 
with a high risk of bleeding, and then transition to a blood 
thinner medication agent, as presented by the AHRQ, a 
government agency in charge of research and quality in 
healthcare systems (Maynard, 2016).
Testing for Factor V Leiden is not commonly done with 
the general population but focuses on family members of 
those with the genetic mutation. In regard to prophylaxis 
agents for long term immobility, such as post-surgery, 
different agents are available and will depend on the pa-
tient’s abilities to self-administer daily injections, as well as 
the risk of bleeding, yet it is always important to measure 
the levels of risk, especially for those patients with a 
genetic component such as factor V Leiden mutation. The 
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factor V Leiden genetic mutation was discovered in rela-
tion with increased risks of VTE for female patients on 
oral contraception. Indeed, it appears that an important 
amount of the research regarding Factor V Leiden throm-
bophilia is associated with female individuals and attend 
to pregnancy or contraception related matters. 
Female Patients with Factor V Leiden-Family Planning
Female patients of child-bearing age who are positive for 
factor V Leiden need to be aware that their genotype can 
affect their choices when dealing with contraception and 
family planning.
Contraception
It is believed that oral contraceptives, especially estrogen 
containing agents have the potential to increase the risk 
of VTE; indeed, the estrogen will increase the plasma con-
centration of certain clotting factors and fibrinogen, all of 
which are favorable to clotting formation (Busti, 2015).
 Although several sources have pushed for testing 
patients for Factor V Leiden prior to prescribing oral 
contraceptives, it represents a large population of female 
patients being tested and consequent precautions to be 
taken for life with constant awareness of the genotype, 
when there is no guarantee one of those women will 
ever experience a thrombosis event. Rather, a review 
suggests recording a comprehensive personal and familial 
medical history or VTE when prescribing oral contracep-
tives (OCP) (Rosendaal, Koster, et. al, 1995), which seems 
more appropriate and targeted. 
It is important to understand that the association of 
factor V Leiden and use of oral contraceptives cause great 
thrombosis risk, and has been long studied and concluded 
as such (Choe, Suh, 2019), therefore a female patient 
should always mention it to her doctor before being 
prescribed any oral contraceptives. Luckily, several con-
traceptive options have become available on the market 
to satisfy all preferences and medical conditions, which 
becomes handy for those with a history of VTE or known 
Factor V Leiden. For example, the oral contraceptives 
containing only progesterone have been categorized as 
little to non-affecting coagulation. Therefore, these can 
become an ideal option for those women at higher risk 
of developing VTE, such as those with factor V Leiden 
genotypes. Similarly, Intrauterine devices (IUD) contain-
ing only progestin, such as the Mirena, are an excellent 
alternative to oral contraceptives for those who can’t 
seem to comply to the daily regimen of birth control, 
especially when indicated to be taken at the same time 
every day. It is however essential to bring to light the fact 
that fewer studies were conducted on progesterone-only 
agents, therefore more data may be necessary to fully 
draw the conclusion of its higher grade of safety in terms 
of VTE prevention (Tchaikovski, Rosing, 2010). In addition, 
The Journal of Community Hospital Internal Medicine 
published an article this year warning about the proges-
tin-only IUD, when a female patient in her early 30’s with 
Factor V Leiden suffered a pulmonary embolism while on 
that intrauterine device (Jean, 2019). Therefore, although 
it appeared at first that only estrogen containing oral or 
intrauterine agents were associated with increased risk 
of VTE incidences, we find it questionable whether the 
progestin only agents are truely safe alternative for those 
patients at risk such as the Factor V Leiden genotypes, 
or even those without the genotype but with a history 
of clotting. Luckily for those individuals, there is now 
a non-hormonal intrauterine device available such as 
the Paragard IUD, releasing copper as a contraception 
method, therefore seemingly the ideal option for those of 
at VTE risk. In its mechanism, the copper acts as a toxic 
environment for sperm, which significantly reduces the 
chance for fertilization of the egg (Higginbotham, 2018).
Though it seems like the ideal option, it is interesting 
to present the reported increase of menstrual bleeding 
associated with the Copper Intrauterine device, as well as 
cramping (Galan, 2016). Furthermore, the idea of having 
an internal device can be disturbing for a lot of patients 
and has shown serious medical consequences such as 
ectopic pregnancies or infections, although only shown in 
low percentages. 
To sum it up, it appears that although ample options 
are available on the market for contraception, the choic-
es become limited for patients with Factor V Leiden or 
patients with personal or even a family history of VTE. 
Although intrauterine devices optimize compliance with 
the regimen, they aren’t always the preferred options 
for contraception due to their potential serious conse-
quences. Ultimately, patients at risk of developing VTE 
should resort to using the copper IUD, because it doesn’t 
contain any hormones, despite its potential increase of 
bleeding risk, which can be even more exacerbated for 
those patients who already take daily anticoagulant.
Factor V Leiden plays an important role in a patient’s 
choice for contraception, but also during pregnancy or 
when planning to become pregnant.
Pregnancy
Pregnancy represents a risk factor on its own for Venous 
Thromboembolism. During pregnancy, a patient will be 
considered in a hypercoagulable state, or increased ten-
dency to coagulate, due to higher levels of fibrinogen and 
certain clotting factors, as well as a vascular damage or 
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reshaping that the increase in weight and fluid can cause 
(Gibson, Powrie, 2009). Following that thought process, a 
risk factor should be avoided, or if cannot be, should be 
carefully managed; in this case management of pregnancy 
for patients at risk of VTE. 
Patients with Factor V Leiden and/or those with a 
history of VTE should carefully monitor their cycles as 
to know when to get pregnant because of the high prob-
ability those individuals will need to modify the types of 
AC they take. Multiple studies have examined the optimal 
options for prophylaxis AC in patients who are at high 
risk of developing VTE or those who have a history of 
VTE. It appears that the current recommendations sug-
gest the use of heparin injections throughout pregnancy 
and up to 6 weeks after delivery, because heparin does 
not cross the placenta and is not transmitted via breast 
milk. Therefore, it is considered a relatively safe option 
for both the mother and baby (Gibson, Powrie, 2009). 
However, while Heparin is safe for pregnancy, it is im-
portant to distinguish between unfractionated heparin, 
which has been linked to osteoporosis and thrombocy-
topenia when used long term, and low molecular weight 
heparin (LMWH), with less incidence of the above men-
tioned (De Santis, et., al, 2006). An example of LMWH 
is Lovenox, with the generic name enoxaparin, and has 
demonstrated success as a prophylactic agent against 
VTE in several instances world-wide, one of which was 
reported regarding a young pregnant patient in Nigeria 
with factor V Leiden homozygous who was treated with 
LMWH during her pregnancy due to a DVT (Dogara, et, 
al, 2018). Since pregnancy might occur while on an anti-
coagulant, it is essential for those individuals to be aware 
of their cycles in order to start the appropriate AC agent 
as soon as soon they become pregnant. The use of direct 
oral anticoagulants (DOACs) are still contraindicated 
during pregnancy. In fact, it is due to the lack of data prov-
ing them safe, the few results demonstrating a high rate 
of miscarriage, as well as relatively significant amount of 
fetal abnormalities for patients on DOACs, concluded to 
be directly related to the DOACs, but poorly investigated 
(Lameijer, et, al, 2018). 
Female patients who are aware of a risk factor for 
VTE, usually genetic such as factor V Leiden mutation, can 
evidently be more prepared and educated on the pre-
cautions to take regarding anticoagulation management 
during pregnancy. However, many patients in fact find out 
about their Factor V Leiden mutation during pregnan-
cy, as they experience a DVT or pulmonary embolism, 
requiring emergency treatment with LMWH, or after 
suffering multiple spontaneous miscarriages. Interestingly, 
some studies have compared the rate of first trimester 
miscarriages in patients with known factor V Leiden and 
those with known regular genotype, and the incidence of 
early pregnancy miscarriage doesn’t seem to have a close 
relationship with Factor V Leiden. Rather it does when 
comparing later term miscarriage, possibly caused by 
clotting within the uterine vasculature (Jivraj, et., al, 2009). 
Furthermore, while Factor V Leiden had been thought 
more risky, it doesn’t appear to affect the management 
of pregnant patients for VTE prevention, since several 
studies have yet to discover significant differences in 
clinical pictures between homozygous and heterozygous, 
(Gat, et, al, 2014).
Other forms of prevention for VTE during pregnancy 
include compression stockings however these have re-
ceived a low grade of compliance among those women 
due to discomfort. Moreover, it usually can improve 
blood circulation in lower extremities but are limited to 
lower extremities.
As with all patients, pregnant patients with factor V 
Leiden should in addition keep a healthy lifestyle, combin-
ing a balanced diet and regular exercise, to keep proper 
perfusion, for theirs and their babies’ sake.
Conclusion
The high incidences of VTE has stimulated much research 
to find optimal forms of treatment and preventative 
agents in the forms of Anticoagulants, whether oral or 
injectable, for patients at higher risk of developing Venous 
thromboembolism, such as those individuals with the 
Factor V Leiden genetic mutation. Although the newer 
DOACs have become more popular due to decreased 
necessity for close monitoring, decreased bleeding risk, 
and statistical efficiency in the prevention of thrombosis, 
it appears they still cause issues for pregnant patients, 
and require more extensive research to prove their safe-
ty. Fortunately, low molecular weight heparin injections 
have been used for management of pregnant patients 
since they don’t cross the placenta, and they have been 
utilized often as a post-surgery prophylaxis on a short-
term basis. Regarding the management of patients who 
wish to utilize contraception measures, careful attention 
is to be applied due to the elevated clinical relationship 
between the use of estrogen and episodes of VTE, but 
unfortunately most of the contraceptive options do not 
seem adequate for those high-risk female individuals, 
therefore requiring further research and development. 
Although Factor V Leiden appears to be the most popu-
lar genotype associated with VTE, multiple other genetic 
mutations have close relationships with increased risk 
of thrombosis. Since the pregnancy represents a high 
risk factor on its own, perhaps the thought of prenatal 
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testing with a thrombophilia panel doesn’t seem inade-
quate, although the question remains about a reasonable 
response to the screenings in terms of prophylaxis, that 
would be beneficial to patients’ physical health without 
being detrimental to their mental health, once aware that 
an important genetic mutation is present, especially at 
sensitive times such as during pregnancy.
References
Anderson, F. (2003). Risk Factors for Venous 
Thromboembolism. Circulation, 107(90231), pp.9I--16.
Benjamin, T. (2018, May 18). Review of Factor V 
Leiden Thrombophilia. Retrieved from Uspharmacist.
com website: https://www.uspharmacist.com/article/
review-of-factor-v-leiden-thrombophilia
Busti, Anthony J. “Dosing Differences and Rationale 
Among Low Molecular Weight Heparins (LMWH; 
Enoxaparin, Lovenox, Dalteparin, Fragmin, Etc).” 
Ebmconsult.Com, Oct. 2015, www.ebmconsult.com/ar-
ticles/lmwh-enoxaparin-lovenox-dalteparin-fragmin-dos-
ing-differences. Accessed 15 Nov. 2019.
Busti, Anthony J. “The Mechanism of Oral Contraceptive 
(Birth Control Pill) Induced Clot or Thrombus 
Formation (DVT, VTE, PE).” Ebmconsult.Com, Oct. 2015, 
www.ebmconsult.com/articles/oral-contraceptive-clot-
ting-factors-thrombosis-dvt-pe. Accessed 12 Dec. 2019.
Choe HJ, Suh KJ, Lee JY, et al. Acute pulmonary throm-
boembolism caused by factor V leiden mutation in south 
korea: A case report. Medicine. 2019;98(28):e16318.
Cuker, A., Burnett, A., Triller, D., Crowther, M., Ansell, J., 
Van Cott, E. M., … Kaatz, S. (2019). Reversal of direct 
oral anticoagulants: Guidance from the Anticoagulation 
Forum. American Journal of Hematology, 94(6), 697–709. 
https://doi.org/10.1002/ajh.25475
Cushman, M. (2007). [online] Ncbi.nlm.nih.gov. 
Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC2020806/pdf/nihms21418.pdf.
De Santis M, Cavaliere AF, Straface G, Di Gianantonio 
E, Caruso A. Inherited and acquired thrombophilia: 
Pregnancy outcome and treatment. Reproductive 
Toxicology. 2006;22(2):227-233.
 Dogara LG, Ovosi JO, Mohammed C, Farouk B, Mafika 
Z, Mahlangu J. Compound homozygous factor V leiden 
and heterozygous prothrombin gene mutation: The first 
report in a pregnant african with extensive thrombosis. 
Blood. 2018;132(Supplement 1):5056.
Galan, N. (2016). Can an IUD Cause a Heavy Period?. 
[online] Healthline. Available at: https://www.healthline.
com/health/birth-control/iud-heavy-period#1 [Accessed 
20 Nov. 2019].
Garcia, David A, and Mark Crowther. “Risks and 
Prevention of Bleeding with Oral Anticoagulants.” 
Uptodate.Com, 13 Aug. 2019, www.uptodate.com/
contents/risks-and-prevention-of-bleeding-with-oral-an-
ticoagulants#!
Gat I, Dulitzki M, Schiff E, Sivan E, Simchen MJ. 
Peripartum thromboprophylaxis for homozygous and 
heterozygous FVL mutation carriers yields similar preg-
nancy outcome. The Israel Medical Association journal: 
IMAJ. 2014;16(2):96.
Gibson, P. S., and R. Powrie. “Anticoagulants and 
Pregnancy: When Are They Safe?” Cleveland Clinic 
Journal of Medicine, vol. 76, no. 2, 1 Feb. 2009, pp. 
113–127, mdedge-files-live.s3.us-east-2.amazonaws.com/
files/s3fs-public/issues/articles/media_abf4a49_113.pdf, 
10.3949/ccjm.75a.072272. Accessed 13 Nov. 2019.
Grody, W. W., Griffin, J. H., Taylor, A. K., Korf, B. R., & 
Heit, J. A. (2001). American College of Medical Genetics 
Consensus Statement on Factor V Leiden Mutation 
Testing. Genetics in Medicine, 3(2), 139–148. https://doi.
org/10.1097/00125817-200103000-00009
Harringa, Adam. “Blood Thinners in Combination 
Increase Bleeding Risk, Mayo Study Finds.” Https://
Advancingthescience.Mayo.Edu, 5 Aug. 2019, advancingth-
escience.mayo.edu/2019/08/05/blood-thinners-in-combi-
nation-increase-bleeding-risk/. Accessed 11 Nov. 2019.
Higginbotham, V. (2018). Copper Intrauterine Device 
(IUD) | The Embryo Project Encyclopedia. [online] 
Embryo.asu.edu. Available at: https://embryo.asu.edu/
pages/copper-intrauterine-device-iud [Accessed 22 Nov. 
2019]
Jean S. Isolated pulmonary embolism in a patient with 
progestin intrauterine device and factor V leiden. Journal 
of Community Hospital Internal Medicine Perspectives. 
2019;9(3):264-266.
Jivraj S, Makris M, Saravelos S, Li TC. Pregnancy outcome 
in women with factor V leiden and recurrent miscar-
riage. BJOG: An International Journal of Obstetrics & 
Gynaecology. 2009;116(7):995-998.
Kearon, C., & Akl, E. A. (2014). Duration of anticoagulant 
therapy for deep vein thrombosis and pulmonary embo-
lism. Blood, 123(12), 1794–1801. https://doi.org/10.1182/
blood-2013-12-512681
Lameijer, H., Aalberts, J. J. J., van Veldhuisen, D. J., Meijer, 
K., & Pieper, P. G. (2018). Efficacy and safety of direct oral 
anticoagulants during pregnancy; a systematic literature 
28
Simha Wolf
review. Thrombosis Research, 169, 123–127. https://doi.
org/10.1016/j.thromres.2018.07.022
Lip, Gregory YH, and Russell D Hull. “Rationale and 
Indications for Indefinite Anticoagulation in Patients with 
Venous Thromboembolism.” Uptodate.Com, 19 Sept. 
2019, www.uptodate.com/contents/rationale-and-indica-
tions-for-indefinite-anticoagulation-in-patients-with-ve-
nous-thromboembolism. Accessed 2 Dec. 2019.
Mayo Clinic. (2018). Warfarin side effects: Watch for in-
teractions. [online] Available at: https://www.mayoclinic.
org/diseases-conditions/deep-vein-thrombosis/in-depth/
warfarin-side-effects/art-20047592 [Accessed 18 Nov. 
2019]
Maynard, Greg. Preventing Hospital-Associated Venous 
Thromboembolism A Guide for Effective Quality 
Improvement. Aug. 2016.
Milling, T., & Frontera, J. (2017). Exploring Indications 
for the Use of Direct Oral Anticoagulants and the 
Associated Risks of Major Bleeding HHS Public Access. 
Am J Manag Care, 23(4), 67–80. Retrieved from https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC5568002/pdf/
nihms893204.pdf
NYU Langone News. (2020). NYU Langone Establishes 
First-of-Its-Kind Center to Diagnose & Treat Deadly 
Blood Clots. [online] Available at: https://nyulangone.org/
news/nyu-langone-establishes-first-its-kind-center-diag-
nose-treat-deadly-blood-clots.
Nyulangone.org. (2020). [online] Available at: https://
nyulangone.org/files/nyu-vtec-venous-thromboembol-
ic-treatment-guidelines-sep-16.pdf.
Ornstein, D. L., & Cushman, M. (2003). Factor V Leiden. 
Circulation, 107(15). https://doi.org/10.1161/01.
cir.0000068167.08920.f1
Paj, Menaka, and James D Douketis. “Prevention of 
Venous Thromboembolism in Adult Orthopedic Surgical 
Patients.” Uptodate.Com, 16 Sept. 2019, www.uptodate.
com/contents/prevention-of-venous-thromboembo-
lism-in-adult-orthopedic-surgical-patients#! Accessed 24 
Oct. 2019.
Perez Botero J, Ormsby WD, Ashrani AA, et al. Do inci-
dent and recurrent venous thromboembolism risks truly 
differ between heterozygous and homozygous factor 
V leiden carriers? A retrospective cohort study. Eur J 
Intern Med. 2016;30:77-81.
Perez Botero J, Ormsby WD, Ashrani AA, et al. 
Prevalence of venous and arterial thrombosis among 
268 heterozygous and 111 homozygous factor V leiden 
carriers: A single-center cross-sectional study. Blood. 
2014;124(21):1536.
 Rees DC, Cox M, Clegg JB. World distribution of factor 
V leiden. The Lancet. 1995;346(8983):1133-1134.
Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. 
High risk of thrombosis in patients homozygous for 
factor V leiden (activated protein C resistance). Blood. 
1995;85(6):1504-1508.
Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value 
of factor V leiden and prothrombin G20210A in adults 
with venous thromboembolism and in family members 
of those with a mutation: A systematic review. JAMA. 
2009;301(23):2472-2485.
Tchaikovski SN, Rosing J. Mechanisms of estro-
gen-induced venous thromboembolism. Thromb Res. 
2010;126(1):5-11.
 Van Cott EM, Khor B, Zehnder JL. Factor V leiden. Am J 
Hematol. 2016;91(1):46-49.
Vandenbroucke JP, Koster T, Rosendaal FR, Briët E, 
Reitsma PH, Bertina RM. Increased risk of venous 
thrombosis in oral-contraceptive users who are 
carriers of factor V leiden mutation. The Lancet. 
1994;344(8935):1453-1457.
Vandenbroucke JP, van der Meer, Felix J M., Helmerhorst 
FM, Rosendaal FR. Factor V leiden: Should we screen 
oral contraceptive users and pregnant women? BMJ. 
1996;313(7065):1127-1130.
Weillcornell.org. (2020). Center for Blood Disorders | 
Weill Cornell Medicine. [online] Available at: https://wei-
llcornell.org/center-for-blood-disorders.
